Lisdexamfetamine dimesylate
Vyvanse (lisdexamfetamine dimesylate) is a small molecule pharmaceutical. Lisdexamfetamine dimesylate was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA. Vyvanse's patent is valid until 2023-02-24 (FDA).
| Trade Name | Vyvanse |
|---|---|
| Common Name | Lisdexamfetamine dimesylate |
| Indication | attention deficit disorder with hyperactivity, binge drinking |
| Drug Class | Amfetamine derivatives |
